Skip to main content

ALX ONCOLOGY HOLDINGS INC

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

ALXO$1.29+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Power of Attorney

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jason Lettmann and Harish Shantharam, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Jason LettmannChief Executive Officer and Director(Principal Executive Officer)March 6, 2025
Jason Lettmann
/s/ Harish ShantharamChief Financial Officer(Principal Financial Officer)March 6, 2025
Harish Shantharam
/s/ Shelly PintoSenior Vice President, Finance and Chief Accounting Officer(Principal Accounting Officer)March 6, 2025
Shelly Pinto
/s/ Corey GoodmanChairman of the Board of DirectorsMarch 6, 2025
Corey Goodman, Ph.D.
/s/ Rekha HemrajaniDirectorMarch 6, 2025
Rekha Hemrajani
/s/ Barbara KlenckeDirectorMarch 6, 2025
Barbara Klencke, M.D.
/s/ Chris TakimotoDirectorMarch 6, 2025
Chris Takimoto, M.D., Ph.D., FACP
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.